Multiple epidemiologic studies show that adeno-associated virus (AAV) is negatively associated with cervical cancer (CX CA), a cancer which is positively associated with human papillomavirus (HPV) infection. Mechanisms for this correlation may be by Rep78's (AAV's major regulatory protein) ability to bind the HPV-16 p97 promoter DNA and inhibit transcription, to bind and interfere with the functions of the E7 oncoprotein of HPV-16, and to bind a variety of HPV-important cellular transcription factors such as Sp1 and TBP. c-Jun is another important cellular factor intimately linked to the HPV life cycle, as well as keratinocyte differentiation and skin development. Skin is the natural host tissue for both HPV and AAV. In this article it is demonstrated that Rep78 directly interacts with c-Jun, both in vitro and in vivo, as analyzed by Western blot, yeast two-hybrid cDNA, and electrophoretic mobility shift-supershift assay (EMSA supershift). Addition of anti-Rep78 antibodies inhibited the EMSA supershift. Investigating the biological implications of this interaction, Rep78 inhibited the c-Jun-dependent c-jun promoter in transient and stable chloramphenicol acetyl-transferase (CAT) assays. Rep78 also inhibited c-Jun-augmented c-jun promoter as well as the HPV-16 p97 promoter activity (also c-Jun regulated) in in vitro transcription assays in T47D nuclear extracts. Finally, the Rep78 -c-Jun interaction mapped to the amino-half of Rep78. The ability of Rep78 to interact with c-Jun and down-regulate AP-1-dependent transcription suggests one more mechanism by which AAV may modulate the HPV life cycle and the carcinogenesis process.
Introduction
Adeno-associated virus (AAV) type 2 is a small nonpathogenic DNA virus which, similar to human papillomavirus (HPV), is productive in stratified squamous epithelium (Meyers et al., 1992 (Meyers et al., , 2000 (Meyers et al., , 2001 , but otherwise requires additional "helper" functions from adeno-, herpes-, or papillomaviruses (Myers et al., 1980; Walz et al., 1997; Weindler and Heilbronn, 1991) . Keratinocyte differentiation within the epithelium is needed for both AAV and HPV productive replication. AAV and HPV are also known to interact in the stratified squamous epithelium generated in vitro with AAV having a dual effect (Meyers et al., 2001) . At low multiplicities of infection (m.o.i.) HPV DNA replication is increased, while at high m.o.i. HPV DNA replication is inhibited. It has been well documented that the cellular transcription factor c-Jun is important for both keratinocyte differentiation (Angel et al., 2001) as well as the HPV life cycle (Cripe et al., 1990; Nurnberg et al., 1995; Hubert et al., 1999) . c-Jun is also involved in HPV-induced oncogenic transformation of cells. The expression profile of c-Jun is positively correlated with expression levels of E6/E7 oncoproteins of HPV (Kyo et al., 1997) . Elevated levels of c-Jun activity are important in advancing cell through G1 phase of cell cycle as c-Jun can transactivate the promotor of cyclin D1 (Bakiri et al., 2000) . E7 of HPV interacts with c-Jun and this leads to enhancement of AP-1 activity and may be a part of the mechanism by which HPV transforms cells (Antinore et al., 1996) .
AAV is known to possess oncosuppressive functions against adenovirus (de la Maza and Carter, 1981; Ostrove et al., 1981) and papillomaviruses (Hermonat, 1989 (Hermonat, , 1994a Hermonat et al., 1997; Horer et al., 1995; Zhan et al., 1999) in tissue culture and epidemiologic studies (Mayor et al., 1976; Georg-Fries et al., 1984; Coker et al., 2001; Smith et al., 2001; Walz et al., 2002) . This property has been attributed to AAV's nonstructural major regulatory protein, Rep78 (Hermonat, 1989 (Hermonat, , 1994 Horer et al., 1995; Zhan et al., 1999) . Rep78, the biggest of four rep proteins, plays a crucial role in AAV replication, transcriptional regulation, and integration Labow et al., 1986; Ni et al., 1994; Tratschin et al., 1984 Tratschin et al., , 1986 Young et al., 2000) . Apart from these essential AAV functions, Rep78 has the ability to interfere with the expression of viral and cellular oncogenes, including those of human papillomavirus type 16 (Hermonat, 1991; Hermonat et al., 1996 Hermonat et al., , 2000 . This is consistent with AAV's known interactions with a variety of transcription factors, including Sp1, TBP, E2F-1, and PCN4 (Batchu et al., 2001; Hermonat et al., 1996 Hermonat et al., , 1998 Weger et al., 1999) . The oncoproteins of HPV have the ability to deregulate the function of essential cellular tumor suppressor proteins such as p53 (Thomas et al., 1999) , pRB (Munger et al., 2001) , and the recent studies of protective activities of Rep78 against p53 degradation (Batchu et al., 1999) , arresting the cells in S-phase through ectopic accumulation of active pRB (Saudan et al., 2000) , and inhibition of E2F-1 activity (Batchu et al., 2001) revealed some of the underlying mechanisms of Rep78-mediated oncosuppression. Because of Rep78's importance in the AAV life cycle, its effects upon the HPV life cycle (both are epithelial-tropic viruses) and HPV oncogenic transformation, and its ability to affect keratinocyte differentiation, we investigated if the Rep78 protein might bind to the c-Jun protein. In this article we demonstrate that Rep78 can bind c-Jun both in vitro and in vivo in yeast and that this association down-regulates transcription from AP-1-dependent promoters.
Results

Rep78 binds c-Jun as demonstrated by Western blot analysis and amino half of Rep78 is required for this interaction
A Far Western blot was initially performed to investigate the possibility of Rep78 binding to c-Jun. The c-Jun and MBP-Rep78 proteins were analyzed in Fig. 1A by SDS-PAGE and are shown to be the expected sizes with some breakdown products, particularly for MBP-Rep78 (common to most preparations). For Far Western blot analysis the MBP-Rep78, MBP, and c-Jun proteins were PAGE or SDS-PAGE separated and electroblotted onto membranes as indicated. In Fig. 1B identical PAGE (non-denatured conditions) generated membranes were probed with either the full-length MBP-Rep78 or the amino-half deleted MBP-Bam-Rep (a deletion of about 243 amino acid residues at the amino end of Rep78). An HRPO enzymatic assay was performed as described under Materials and methods using anti-Rep antibody. As can be seen in Fig. 1B MBP-Rep78 was able to bind to membrane-bound MBP-Rep78 and to c-Jun, while MBP was not recognized. In contrast, MBP-Bam-Rep was only able to bind MBP-Rep78 and c-Jun was not recognized by MBP-Bam-Rep. Fig. 1C shows a near identical experiment in which the proteins to be Western blotted were separated by SDS-PAGE (denatured conditions). As in Fig. 1B , MBP-Rep78 recognized itself and c-Jun, while MBP-Bam-Rep recognized only MBP-Rep78. These data suggest that Rep78 has the ability to bind c-Jun. Furthermore, the inability of MBP-Bam-Rep78 to bind c-Jun suggests that the amino-half of Rep78 is required for this interaction. The same region of Rep78 is known to be required for recognition of Sp1 (Hermonat et al., 1996) . 
Rep78 binds c-Jun in vivo by yeast two-hybrid cDNA analysis
To verify Rep78/c-Jun interaction in living cells, the yeast two-hybrid cDNA assay was used. The plasmid construct pBD-Rep78 fused the GAL4 DNA binding domain ORF to the Rep78 ORF, while pAD-c-Jun fused the GAL4 transactivation domain and c-Jun ORF. Similar plasmids, AD-T Ag and AD-E1A, were constructed containing the SV40 large T antigen and adenovirus type 2 E1A in place of c-Jun. These plasmids, either alone or in combination, were transfected into yeast; the yeast cells were then doubleselected on plates lacking tryptophan and leucine. Cell extracts were prepared and resulting ␤-galactosidase activity was measured. Negative control transfections included BD-Rep78ϩAD-p53, BD-Rep78ϩAD-LaminC, BDϩAD-T Ag, BDϩAD-E1A, and BDϩAD-Jun (no interaction). Positive control transfections included BD-Rep78ϩAD-Sp1, BD-Rep78ϩAD-TBP, BD-Rep78ϩAD-T Ag, and BD-Rep78ϩAD-E1A. All of these protein combinations are known to interact. The results are shown in Fig. 2 . The positive and negative controls gave results as expected. Most importantly the combination of BD-Rep78ϩAD-Jun gave a strong signal, comparable to that of BD-Rep78ϩAD-TBP. These data strongly support the Western blot data, suggesting that Rep78/c-Jun interaction can take place at significant levels within the living cell.
Rep78 binds c-Jun in vitro as shown by EMSA supershift analysis
As c-Jun is a DNA binding transcription factor, we investigated if Rep78 might alter the c-Jun/DNA complex.
Rep78 -c-Jun interaction might sterically inhibit the c-Jun-DNA interaction or, alternatively, Rep78 might be added to the complex. Such changes can be observed using the EMSA assay. In Fig. 3 c-Jun is shown to bind and shift a 32 P-labeled 24-base double-stranded DNA substrate (from the human papillomavirus type 16 p97 promoter region) containing the consensus c-Jun binding motif (Fig. 3 , lane 5). This binding of c-Jun to its motif was specific as addition of 50 molar excess of unlabeled DNA competitor diminished the strength of the shifted band (Fig. 3, lane 6) . This is in contrast to the addition of unlabeled DNA competitor with a mutation within the c-Jun motif DNA (see Materials and methods), which had no effect (Fig. 3, lane 7) . MBP-Rep78 alone was unable to bind the jun-motif-DNA (Fig. 3 , lane 9). However, the addition of MBP-Rep78, along with c-Jun, resulted in the formation of a new higher and stronger complex above the c-Jun-DNA complex, suggesting c-Jun-Rep78 interaction (Fig. 3, lane 4) . The specificity of Rep78 -c-Jun-DNA complex formation was further challenged with anti-Rep78 antibody. It was found that the addition of these anti-Rep antibodies inhibited the formation of Rep78 -c-Jun-DNA complexes in a dose-dependent manner (Fig. 3, lanes 1-3) . The addition of MBP alone had no influence on c-Jun-DNA complex formation (Fig. 3 , lane EMSA showing the in vitro interaction of MBP-Rep78 (0.5 g) with c-Jun (0.3 g). The c-Jun-Rep78 super shift was clear only when the gel was run for a long time, thus the free probe was run off the gel. Increasing the gel concentration compromised the super shift. Therefore, two gels with the same set of samples were run at the same time; one ran for a short time to see the free probe and another for super shift, both are shown, top and bottom. c-Jun binds to the AP-1-motif oligonucleotide and the strength of the shifted band is unaffected in presence of cold, mutant competitor but is affected in presence of cold, AP-1 specific competitor. Note that a new complex containing c-Jun/Rep78 and DNA was formed above the c-Jun-DNA complex when MBP-Rep78 was added. Addition of MBP alone had no effect. Anti-Rep78 antibodies decreased the strength of this new complex in a dose-dependent manner. Histogram showing the quantitated ␤-galactose activities of yeast extracts obtained after transfecting yeast with the indicated plasmid constructs. Note that Rep78 interaction with c-Jun is quite strong, comparable with Rep78/TBP and Rep78/Sp1 interaction. 8). These data further support the Western blot and yeast two-hybrid cDNA analyses, all indicating Rep78 interaction with c-Jun. These data also suggest that c-Jun can bind both its DNA substrate and Rep78 simultaneously.
Rep78 inhibits transcription from the c-jun promoter by CAT assay
To investigate the biological implications of Rep78 -c-Jun interaction, transient transfection assays were performed to study chloramphenicol acetyl (CoA) transferase product expression from a c-Jun-dependent promoter. The c-jun proto-oncogene promoter, itself, is c-Jun-responsive (Angel et al., 1988) . In a transient assay system SW13 cells were calcium phosphate transfected with 4 g of c-jun promoter-CAT plus 8 g d110 -37 (ϪRep78) or pKEX-Rep78 (ϩRep78) ( Fig. 4A and B) . The murine osteosarcomavirus long terminal repeat (MSV-LTR) was also used as a largely Rep78-insensitive control (very few of such promoters have been identified, Hermonat et al., 1996) . Analysis of the MSV-LTR promoter sequence indicates that there are no c-Jun recognition motifs, consensus or closely related (5 of 6), present within the promoter. A quantification of the results is shown in Fig. 4A , and a representative CAT assay (of three) is shown in Fig. 4B . As can be seen in Fig. 4A and B transfection of Rep78 expression plasmid pKEX-Rep78 decreased c-Jun driven CAT activity by 82%, while the MSV-LTR was inhibited by 22%. The positive and negative control plasmids (pSV2-CAT and pA 10 -CAT, respectively) gave the expected CAT activities. It should also be noted that pKEX-Rep78 expresses only the Rep78 protein and not the smaller, related Rep68, Rep52, or Rep40 (Horer et al., 1995) . In a second CAT assay, designed to study Rep78 dosage effects, SW13 cells were calcium transfected with 4 g of c-jun promoter-CAT plasmid plus increased amounts of pKEX-Rep78 plasmids (Fig. 4C ). As can be seen in Fig. 4C transfection of increasing amounts of KEX-Rep78 resulted in a dose-dependent decrease of c-Jun driven CAT activity.
In a stable CAT assay, HeLa cells were calcium phosphate transfected with 2 g of c-jun promoter-CAT plasmid plus 2 g of either pSV2-Neo (ϪRep78) or d152-91/Neo (ϩRep78). Additional proto-oncogene promoter-CAT plasmid constructs were used as controls, including c-fos, cmyc, c-H-ras. The cells were G418 selected for 3 weeks and the G418-resistant colonies were pooled, and lysates were made for CAT enzyme activity. As can be seen in Fig. 4D cotransfection of the c-jun promoter-CAT plasmid with d152-91/Neo (ϩRep78) resulted in down-regulation of CAT activity compared to cotransfection with pSV2-CAT (ϪRep78). These data further support the transient CAT assay finding that Rep78 inhibits c-Jun-dependent promoter activity. In the controls Rep78 inhibited CAT activity from the c-fos, c-myc, c-H-ras proto-oncogene promoters as expected (Hermonat, 1991 (Hermonat, , 1994b ). Rep78. SW13 cells were transfected with c-Jun-CAT or murine osteosarcoma virus LTR-CAT plasmid and different amounts of dl10 -37(ϪRep78) or pKEX-Rep78(ϩRep78). Extracts were prepared from the transfected cells, equalized for the protein amount and assayed for CAT activity. A quantification of the results is shown in (A) and a representative experiment (of three) is shown in (B). Note that the c-jun promoter was sensitive to Rep78 inhibition, while the MSV-LTR promoter was largely insensitive. (C) Dosage-dependent inhibition of c-Jun-dependent promoter by Rep78 in a transient assay. SW13 cells were transfected with c-jun-CAT plasmid (4 g) and different amounts of pKEX-Rep78(ϩRep78) (1, 3, and 10 g). Extracts were prepared from the transfected cells, equalized for the protein amount, and assayed for CAT activity. Note that with increasing amounts of pKEX-Rep78 increased inhibition of CAT expression resulted. (D) Inhibition of c-jun promoter activity by Rep78 in a stable CAT assay. HeLa cells were transfected with c-jun-CAT, c-fos-CAT, c-ras-CAT or c-myc-CAT plus pSV2-Neo (ϪRep78) or dl52-91-Neo (ϩRep78), selected for G418 resistance, and extracts assayed for CAT activity. Note that in presence of Rep78, CAT activity from c-jun-CAT is diminished. Also note that the CAT activity from control plasmid constructs was decreased.
Rep78 inhibits c-Jun augmented transcription in vitro in nuclear extracts
To further investigate the biological significance of Rep78/c-Jun interaction we assayed these proteins in in vitro transcription assays in T47D nuclear extracts. A c-junpromoter DNA fragment/transcription substrate was generated by PCR amplification which contained the c-jun protooncogene promoter and the upstream sequences of CAT as described under Materials and methods. The substrate promoter DNA, the c-Jun, MBP-Rep78, MBP proteins and [␣ 32 P]CTP were added to nuclear extracts as indicated and the products were analyzed by UREA-PAGE as shown in Fig. 5A . As seen the addition of c-Jun protein increased transcription from the c-Jun promoter, and when MBP-Rep78 was added along with c-Jun, c-Jun-dependent transcription was inhibited. In three experiments, under the standardized conditions of 1.2 g of c-Jun added compared to 1.2 g of c-Jun plus 2.0 g of MBP-Rep78 added (a stochiometric ratio of 1-to-1), transcription from the c-jun promoter was inhibited by 69.5 Ϯ 15.5%. In contrast, the addition of MBP protein had little or no affect on c-Junaugmented transcription. The addition of MBP-Rep78, alone resulted in undetectable transcription. The responsiveness of the c-jun promoter was further analyzed to verify that we were observing c-Jun-dependent transcription from the c-jun promoter. As can be seen in Fig. 5B the level of CAT transcripts was increased in a dosage-dependent fashion with the addition of further c-Jun protein. Thus, even though the nuclear extracts had an endogenous level of c-Jun and could carry out a basal level of transcription (Fig.  5B, lane 1) , we could augment the level of c-Jun-dependent transcription by the addition of additional c-Jun protein (Fig. 5B, lanes 2-4) . A third type of nuclear extract transcription experiment (Fig. 5C ) was carried out in which the level of added c-Jun protein was kept constant, but in which increasing amounts of MBP-Rep78 were added. As can be seen the addition of MBP-Rep78 protein inhibited the c-Jun augmented transcription in a dosage-dependent fashion.
A second DNA fragment/transcription substrate was generated by PCR amplification which contained the HPV-16 p97 promoter and the upstream sequences of CAT as described under Materials and methods. This promoter is also known to be c-Jun responsive (Cripe et al., 1990; Hubert et al., 1999; Nurnberg et al., 1995) . The p97-CAT substrate promoter DNA, the c-Jun, MBP-Rep78, MBP, and GST proteins, and [␣ 32 P]CTP were added as indicated to nuclear extracts and the products were analyzed by UREA-PAGE as shown in Fig. 6A . As can be seen the HPV-16 p97 promoter, as expected, was also found to be c-Jun responsive in nuclear extracts. Furthermore, the addition of MBP-Rep78 inhibited this c-Jun-augmented transcription. In three experiments, under the standardized conditions of 1.2 g of c-Jun added compared to 1.2 g of c-Jun plus 2.0 g of MBP-Rep78 added (a stochiometric ratio of 1-to-1), transcription from the p97 promoter was inhibited by 72.8 Ϯ 11.5%. In contrast, MBP and GST had no affect. Finally, the addition of the anti-Rep antibody abrogated inhibition by MBP-Rep78 in a dose-dependent manner. A second type of experiment (Fig. 6B ) demonstrated that the p97 promoter was also transactivated in a dose-dependent manner by the increasing amounts of c-Jun protein. Finally, in Fig. 6C it is shown that increasing amounts of MBP-Rep78 inhibited p97-Jun transactivated transcription (constant c-Jun) in a dose-dependent manner.
Discussion
The present study demonstrates that the Rep78 and c-Jun proteins interact and that this interaction causes a downregulation of c-Jun-dependent transcription. Both AAV and HPV are cutaneous tissue-tropic viruses, productively rep- licating in differentiating keratinocytes. The importance of c-Jun functions for keratinocyte differentiation, the HPV life cycle, and HPV-dependent oncogenic transformation are evident from many previous studies (Angel et al., 2001; Cripe et al., 1990; Hubert et al., 1999) . The expression of the E6 and E7 proteins of HPV is positively regulated by c-Jun (Kyo et al., 1997) . c-Jun is also at a control point in the cell cycle and that manipulation and modulation of c-Jun by viral proteins is a point of removal of cell growth inhibition. E7 of HPV-16 targets c-Jun and up-regulates its activity, which is needed for deregulating the cell-cycle controlling point. The interaction of the E7 with c-Jun could be an important factor along with E7 interaction with pRB, as the latter interaction alone is not sufficient enough for transformation (Fogel and Risu, 1998) . The observation that c-Jun deletion mutants, that are able to interact with E7 but impaired in their transactivation abilities, are unable to mediate transformation showed the importance of c-Jun mediation (Antinore et al., 1996) . Similarly, when c-Jun protein levels were brought down using antisense oligonucleotides which targeted c-Jun RNA, the transformed phenotype was abolished in HPV-transformed cells (Chen et al., 1994) . Now, knowing the importance of c-Jun in the HPV life cycle, Rep78 interaction with c-Jun might have many mechanistic implications.
It has been reported that the composition of AP-1 complex differs between normal and HPV transformed cells. In normal cells c-Jun pairs predominantly with Fra-1, whereas in HPV transformed HeLa cells c-Fos levels are increased over Fra-1. Thus, c-Fos might be the favored partner of c-Jun and this change in composition of the AP-1 complex might be important for HPV-induced transformation (Soto et al., 1999) . It is interesting to note that c-Jun is able to bind DNA and the Rep78 protein simultaneously (Fig. 4) . This is true of course for the c-Jun/c-Fos heterodimer AP-1, and related c-Jun-based complexes. In this study we also observed that in presence of Rep78, c-Jun's DNA binding efficiency was also increased (Fig. 2) , in a similar manner as c-Fos (Halazonetis et al., 1988) . However, unlike the interaction of c-Fos with c-Jun, the interaction of Rep78 with c-Jun affected the transactivation capabilities of c-Jun in a negative manner. This suggests that Rep78 may alter c-Jundependent transcription by inhibiting c-Jun binding to needed transcriptional partners/cofactors such as c-Fos, possibly through steric inhibition. Thus the c-Jun/Rep78 complex might be viewed under this hypothesis as a dominantnegative AP-1 mimic. An alternative hypothesis is that the c-Jun/Rep78 complex may attract a new set of transcription factor interactions entirely different from the traditional AP-1 complex. This new set of transcription factors might have a much different signal transduction outcome. Instead of HPV p97 promoter-or c-jun-promoter-c-Jun-dependent transcriptional up-regulation and cell-cycle progression, the end result would be down-regulation and cell-cycle arrest. Regarding the HPV-16 p97 promoter, yet a third alternative might be that the c-Jun/Rep78 complex, bound at c-Jun's normal binding sites, might interact through Rep78 -Rep78 interaction with adjacent downstream Rep78 homocomplexes bound within HPV-16 p97 promoter (Zhan et al., 1999) . Such DNA-Rep78/Rep78-DNA supercomplexes have been shown to exist (Weitzman et al., 1994) . Finally, a fourth mechanism of inhibition, which seems well substantiated, might be through the direct down-regulation of the c-jun gene itself. With less c-Jun protein being expressed, less c-Jun/AP-1-dependent transcription will result. This should also inhibit progression through the cell cycle. With the likelihood that Rep78 interferes with both c-Jun protein activity and c-jun proto-oncogene expression, we can predict a possible bimodal affect. First, Rep78 can immediately bind and alter c-Jun protein complexes already present within the cell. Second, the extended temporal af- fects of Rep78 would be the overall lowering of c-Jun concentrations within the cell. In any case, the present study does not address the question of whether Rep78 may supplant c-Fos. This question will soon be addressed in planned experiments. Also we have not addressed whether Rep78 can disrupt c-Jun-E7 heterodimers. However, by virtue of its ability to interact with both partners Rep78 might very well affect E7/c-Jun complex formation.
Another aspect that needs to be discussed is the possible importance of Rep78/c-Jun interaction with respect to the AAV life cycle. It is worth considering that AAV is also epithelial tropic virus and can replicate autonomously in differentiating keratinocytes without helper functions from HPV or any other virus (Meyers et al., 2000) . As c-Jun is clearly involved in keratinocyte differentiation, it can be extrapolated that c-Jun might be a relevant transcription factor for AAV autonomous replication as it is for HPV. This hypothesis can be tested by using wild-type and mutant c-Jun proteins. In summary, Rep78, the main regulatory protein of AAV, exerts antiproliferative actions against HPV and this is brought about in multiple ways. Here we have demonstrated Rep78/c-Jun interaction as yet another possible mechanism of controlling HPV-induced transformation by AAV.
Materials and methods
Cells, plasmids, proteins
Human HeLa and SW13 cells were grown in DMEM with 7% fetal bovine serum, 100 g/ml penicillin, and 100 g/ml streptomycin. The plasmids pSV2-Neo, d152-92/ Neo, MBP-Bam-Rep (previously known as Bam-Rep), AD-p53, AD-pLaminC, AD-TBP, AD-Sp1, BD, BD-Rep78, the c-Jun-dependent plasmid c-jun promoter-CAT plasmid (previously known as p-132/ϩ170 Jun-CAT), LTR-CAT, p97-CAT, and the AAV plasmids dl10-37, dl52-91/Neo, and pKEX-Rep78 have been previously described (Batchu et al., 1995 ; Hermonat, 1994b; Hermonat et al., 1996 Hermonat et al., , 1998 Horer et al., 1995; Zhan et al., 1999) . AD-Jun, AD-T Ag, AD-Ad E1A were constructed by similar technique to that of AD-TBP (Hermonat et al., 1998) . MBP-Rep78 construction, MBP, MBP-Rep78 protein production, and purification was described elsewhere (Batchu et al., 1995) . c-Jun protein was obtained from Promega (Madison, WI).
Yeast Gal4 two-hybrid cDNA analysis
Basic reagents and protocols for this assay were procured from the HybriZap two-hybrid cDNA giga pack cloning kit (Stratagene, La Jolla, CA). Construction of plasmids pBD-Rep78, pAD-SP1, pAD-p53, and pAD-laminC was described elsewhere (Hermonat et al., 1998 . Plasmids AD-Jun, AD-T Ag, and AD-E1A were constructed by clon-ing the c-Jun, SV40 large T antigen, and adenovirus type 2 E1A open reading frames (ORF), respectively, in-frame with the Gal4 transactivation domain in the plasmid pGal4-AD. Yeast strains YRG-2 were transformed with the plasmid constructs using lithium acetate method and transformed yeast clones were selected on medium lacking tryptophan and leucine. ␤-Galactosidase activity was quantitated from the transformed clones as described .
Electrophoretic mobility shift assay (EMSA)
For EMSA analysis a full complementary doublestranded oligonucleotide substrate was designed from p97 promoter of HPV-16 (nt 7621 to 7644), which contained an AP-1 consensus sequence, TGAGTCA. A mutated version of this substrate was also designed in which the AP-1 consensus sequence was altered to ATATTTA. The binding reactions were performed in a total of 20 l as described previously (Zhan et al., 1999) . Briefly, 1 ng of 32 P-labeled DNA substrate was incubated with c-Jun or MBP-Rep78 or both as per the experimental need. When indicated, polyclonal anti-Rep antibody (provided by James Trempe) was preincubated with MBP-Rep78 at room temperature for 15 min before addition of c-Jun. For competitive experiments, 50 molar excess of unlabeled AP-1-specific or nonspecific oligos were preincubated with c-Jun for 15 min at room temperature before adding the labeled oligo. The proteinprotein/DNA complexes were analyzed on a 4% polyacrylamide gel with 5% glycerol under low ionic conditions (0.25ϫ TBE). Gels were then dried and exposed with an intensifying screen at Ϫ80°C.
Western blot analysis
MBP-Rep78, c-Jun, and MBP were separated by either SDS-PAGE or PAGE and electroblotted onto a nitrocellulose membrane. The protein blots were incubated with unlabeled MBP-Bam-Rep (10 g/ml) or MBP-Rep78 (10 g/ ml) after a BSA blocking step. Blots were probed by incubating with 1:200 dilution of polyclonal anti-Rep rabbit antibody for 30 min at room temperature with constant agitation. The blots were then subjected to three washings for 10 min each with constant agitation. For enzymatic probing, the blots were incubated with 1:10,000 dilution of rabbit antibodies conjugated to HRPO for 30 min at room temperature with agitation. After extensive washings, blots were incubated in peroxidase enzymatic assay solution consisting of 5 mg 4-chloraphthol substrate and 10 l H 2 O 2 . After the appearance of the bands, the blot was thoroughly rinsed with water and dried (Hermonat et al., 1996) .
Transient and stable CAT assays
Transient CAT assays were carried out in SW13 cells using calcium phosphate transfection method (Stratagene Transfection Kit as per manufacturer's instructions). SW13 cells were transfected with 4 g of c-jun-CAT plus different amounts, as indicated, of dl10-37 (does not express Rep78) or pKEX-Rep78 (expresses Rep78). pSV2-CAT and pA 10 -CAT were the positive and negative controls, respectively. Forty-eight hours after transfection, cell extracts were prepared, equalized for protein content, and assayed for CAT activity as described previously (Hermonat et al., 1996) . For stable CAT assays, HeLa cells were calcium phosphate transfected with 2 g of a CAT expression plasmid (either c-jun-CAT, c-ras-CAT, c-myc-CAT, or c-fos-CAT) plus 2 g of a Neo expression plasmid (either pSV2-Neo [ϪRep78] or dl52-91/Neo [ϩRep78]). Selection was done on 800 g/ml of G418. Extracts were made from the resistant cells (20 -40 colonies each) 4 weeks after G418 selection, equalized for protein content, and assayed for CAT activity as described (Hermonat et al., 1996) .
In vitro transcription in nuclear extracts
A c-jun-CAT DNA fragment (ϳ628 bp), obtained by performing PCR on plasmid Ϫ132/ϩ170 Jun-CAT using primers (5Ј GCCTCTTCGCTATTA CGCCAGTCG 3Ј and 5Ј CATATCACCAGCTCACCGTC 3Ј), and a p97-CAT DNA fragment (1.2 kb) generated by PCR using the primers and the template described earlier (Zhan et al., 1999) , were used as templates in in vitro transcription analysis. The reactions were carried out at 30°C for 1 h in a total of 25 l containing 15 g of T-47D nuclear extract (Geneka Corp., Montreal, Canada; HPV negative breast ductal carcinoma) as described earlier (Zhan et al., 1999) . The reactions were terminated by adding 175 l of stop mix containing 0.3 M Tris-HCl (pH 7.9), 0.3 M sodium acetate, 0.5% SDS, 2 mM EDTA, and 3 g/ml tRNA. The mixture was then extracted with phenol:chloroform:isoamyl alcohol (25:24:1) and the RNA was precipitated by ethanol. The RNA was dissolved in 10 l loading buffer (98% formamide, 10 mM EDTA, and 0.1% bromphenol blue) and analyzed on 6% acrylamide, 7 M urea, 1ϫ TBE gel. The gel was dried and exposed to X-ray film with an intensifying screen at Ϫ80°C.
